RBC Capital Keeps a Buy Rating on Agile Therapeutics (AGRX)

By Jason Carr

In a report released today, Randall Stanicky from RBC Capital reiterated a Buy rating on Agile Therapeutics (AGRXResearch Report), with a price target of $8.00. The company’s shares closed last Monday at $1.85.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -21.5% and a 18.4% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Agile Therapeutics is a Strong Buy with an average price target of $7.80, which is a 306.3% upside from current levels. In a report issued on March 20, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.77 and a one-year low of $0.35. Currently, Agile Therapeutics has an average volume of 3.96M.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGRX in relation to earlier this year. Last month, Alfred Altomari, the CEO of AGRX bought 16,541 shares for a total of $11,744.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.